Natera Company Profile (NASDAQ:NTRA)

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.52) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.52). The company earned $53.60 million during the quarter, compared to analyst estimates of $50.57 million. Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The firm's revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.46) EPS. View Natera's Earnings History.

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Natera.

4 brokerages have issued twelve-month target prices for Natera's shares. Their predictions range from $13.00 to $20.00. On average, they expect Natera's stock price to reach $15.75 in the next twelve months. View Analyst Ratings for Natera.

Here are some recent quotes from research analysts about Natera stock:

• 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (8/12/2017)
• 2. Cowen and Company analysts commented, "Subsequent to the company's Q4 conference call (last week), we are reducing our estimates to reflect management commentary and 2017 guidance. While we believe the risk/reward is likely attractive at current levels, we are also reducing our price target to reflect our new revenue forecast and the heavy-H2 weighting of 2017 expectations...NTRA reported Q4 results last week and provided 2017 revenue guidance. In advance of the company's conference call (link to note), we had reduced our revenue estimates for Q4 and for 2017, by $1.5MM and $13MM, respectively, to reflect our estimated impact of the termination of the company's distribution agreement with BioReference Labs. Our reductions put us at the low end of the range of sell side estimates. Unfortunately, our estimates were not low enough for either period. Shares have traded off ~15% since the announcement and are off nearly 30% YTD." (3/14/2017)

Some companies that are related to Natera include Lexicon Pharmaceuticals (LXRX), Immunomedics (IMMU), OraSure Technologies (OSUR), Accelerate Diagnostics (AXDX), BAVARIAN NORDIC (BVNRY), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Varex Imaging (VREX), Aimmune Therapeutics (AIMT), LHC Group (LHCG), Dermira (DERM), Dynavax Technologies Corporation (DVAX), Epizyme (EPZM), Mazor Robotics (MZOR), Esperion Therapeutics (ESPR) and Glaukos Corporation (GKOS).

Natera's management team includes the folowing people:

• Matthew Rabinowitz Ph.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Jonathan Sheena, Co-Founder, Chief Technology Officer, Director
• Michael Burkes Brophy, Chief Financial Officer
• Roelof Frederick Botha, Lead Independent Director
• Todd C. Cozzens, Independent Director
• Edward C. Driscoll Jr. Ph.D., Independent Director
• James I. Healy M.D. Ph.D., Independent Director
• Gail Boxer Marcus, Independent Director

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital World Investors (7.93%), Jennison Associates LLC (4.46%), Vanguard Group Inc. (4.28%), Sofinnova Management VIII L.L.C. (2.93%), Macquarie Group Ltd. (2.00%) and Franklin Resources Inc. (1.97%). Company insiders that own Natera stock include Herm Rosenman, Jonathan Sheena, Matthew Rabinowitz and Roelof Botha. View Institutional Ownership Trends for Natera.

Natera's stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Citadel Advisors LLC, Nationwide Fund Advisors, Prudential Financial Inc., Capital Impact Advisors LLC, Hamilton Lane Advisors LLC and Goldman Sachs Group Inc.. Company insiders that have sold Natera stock in the last year include Herm Rosenman, Jonathan Sheena and Matthew Rabinowitz. View Insider Buying and Selling for Natera.

Natera's stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Broadview Advisors LLC, Vanguard Group Inc., Kornitzer Capital Management Inc. KS, Asymmetry Capital Management L.P., Spark Investment Management LLC, Northern Trust Corp and PDT Partners LLC. View Insider Buying and Selling for Natera.

Shares of Natera can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Natera stock can currently be purchased for approximately $12.63.